Loading clinical trials...

TERMINATEDPHASE3

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris

NCT02613910•GlaxoSmithKline

Summary

This study is designed as a multi-country, multicenter, open label extension to Phase III trial OPV116910. The primary objective is to provide continued treatment with ofatumumab subcutaneous (SC) for eligible subjects who complete the OPV116910 trial in order to obtain further long term safety and tolerability information in subjects with pemphigus vulgaris receiving ofatumumab SC every 4 weeks (wk).

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult with clinically documented diagnosis of PV.
•Completed Study OPV116910 through Week 60 with one of the following outcomes:
•Did not achieve remission by Week 60 of OPV116910. Achieved remission on a steroid dose \>10 milligrams/day. Achieved remission on minimal steroid therapy, but is experiencing a disease flare/relapse while participating in the first year (yr)of the OPV116910 Individualized Follow up Period (It is recommended subjects are transitioned to the extension study before the steroid dose is increased).
•A woman is eligible to enter the study if she:
•Is of non-childbearing potential: documented as surgically sterile (bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion) or is postmenopausal without menses for \>2 years. Women who are \<2 years postmenopausal are required to have menopausal status confirmed by follicle-stimulating hormone (FSH) and estradiol levels at the baseline evaluation. If FSH and estradiol levels do not provide confirmation of menopause, subject will be considered to be of childbearing potential.
•Is of childbearing potential, with a negative pregnancy test at baseline, and agrees to the consistent and correct use of acceptable methods of contraception (Highly-Effective Methods for Avoiding Pregnancy) during heterosexual intercourse, beginning when the subject provides informed consent and lasting until 12 months after last dose of ofatumumab SC.

Exclusion Criteria

•Past or current history of hypersensitivity to components of the investigational product or medically-significant adverse effects (including allergic reactions) from cetirizine (or antihistamine equivalent) or paracetamol/acetaminophen.
•Prior treatment with any of the following within the specified periods:
•Medication and Other Treatment Restrictions Prior to OPV117059 Baseline Any time- Ofatumumab (Intravenous), total body irradiation, bone marrow transplantation, anti CD4; 6 weeks -Live vaccine 8 weeks- Immunosuppressive or immunomodulatory agents, including: azathioprine, cyclosporine, dapsone, mycophenolate, methotrexate, tacrolimus 6 months- Cyclophosphamide, cladribine, plasmapheresis, immunoabsorption, or immunoglobulin therapy, alemtuzumab, mitoxantrone 18 months -Rituximab or other anti CD20 treatments
•Confirmed PML or neurological findings potentially consistent with PML.
•Evidence or history of clinically significant infection or medical condition including:
•Chronic or ongoing active infectious disease requiring long term systemic treatment, including, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, or active hepatitis C.
•Positive test for hepatitis B surface antigen (HbsAg). For HbsAg negative, but hepatitis B core antibody positive (anti-HBc) (regardless of hepatitis B surface antibody \[HbsAb\] status), a hepatitis B virus deoxyribonucleic acid (HBV DNA) test will be performed and the subject will be excluded if results are positive. Consult with a physician experienced in the care and management of subjects with hepatitis B to manage/treat subjects who are anti HBc positive. Subjects who are anti-HBc positive and HBV DNA negative will continue to be monitored throughout the study.
•History of positive serology for human immunodeficiency virus. Previous serious opportunistic or atypical infections. Prior history, or suspicion, of tuberculosis. A radiograph of the chest taken within 3 months before the first administration of investigational product suggests no evidence indicating current active tuberculosis or previous tuberculosis.
•Past or current malignancy, except for: Cervical carcinoma Stage 1B or less; Noninvasive basal cell and squamous cell skin carcinoma; Cancer diagnoses with a duration of complete response (remission) \>5 years.
•Clinical chemistry and/or hematology laboratory values of clinical concern, in the investigator's opinion.
+6 more criteria

Locations (2)

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Ann Arbor, Michigan, United States

Key Dates

Start Date

December 23, 2015

Primary Completion Date

March 23, 2016

Completion Date

March 23, 2016

Last Updated

June 14, 2017

Enrollment

ACTUAL participants

Conditions

Pemphigus

Interventions

Ofatumumab

DRUG

Acetaminophen/paracetamol

DRUG

Antihistamine (cetirizine or equivalent)

DRUG

Prednisone/Prednisolone

DRUG

Autoimmune Blistering Diseases Study

NCT02753777

Pemphigus VulgarisPemphigus Foliaceus+1 more

View study

TERMINATEDPHASE3

A Study of PRN1008 in Patients With Pemphigus

NCT03762265

Pemphigus

View study

TERMINATEDPHASE1/PHASE2

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 14, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Inclusion Criteria

Exclusion Criteria

Autoimmune Blistering Diseases Study

A Study of PRN1008 in Patients With Pemphigus

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus